Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days

COVID-19

Ivermectin plus Nitazoxanide

Standard Care

Ivermectin and Nitazoxanide Combination Therapy for COVID-19

Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope

improved breaths per minute for the patients

Serum iron in microgram/dL of the patients

Serum ferritinin microgram/L of the patients

International normalized ratio "INR" for prothrombin time of 2

CBC for lymphocyte count in cells/microliter

Mortality rate [number of dead patients/total number of treated patients]

Prof. Dr. Kamal Mohammed Okasha

Vice-President of Postgraduate Studies and Research Affairs

Tanta University

This study will be a double blind randomized controlled parallel study

Emtricitabine 200mg/tenofovir alafenamide 25mg (FTC/TAF) tablet to be given orally once daily to be added to a failing regimen for 10 days. If HIV RNA decline by >= 0.5 log copies/mL, patient will continue on FTC/TAF with a new antiretroviral regimen for 48 weeks. If < 0.5 log copies/mL decline, patient will be taken off FTC/TAF.

Each subject receives tenofovir alafenamide (TAF) with emtricitabine to be added to a failing antiretroviral regimen for 10 days, if there is a HIV RNA response of >= 0.5 log decline, subjects will continue of TAF with emtricitabine with a new optimized background regimen. If <0.5 log decline, TAF with emtricitabine will be discontinued and study enrollment for the subject will be terminated.

TAF Treatment

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

An HIV RNA decline of >=0.5 log by day 10 will be considered to be an adequate virologic response, to proceed to the second phase of the study.

HIV RNA Change From Baseline to Day 10

Overall Study

Alice Pau, Pharm.D., Staff Scientist (Clinical)

Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir. This trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part of a salvage antiretroviral regimen for HIV-1-infected adults and adolescents (greater than or equal to 14 years) who experienced virologic failure.

FTC/TAF

National Institutes of Health Clinical Center, 9000 Rockville Pike

Emtricitabine/Tenofovir Alafenamide as Salvage ART

Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide as Part of Salvage Antiretroviral Regimens in Patients With Uncontrolled Viremia and Drug-Resistant HIV Infection

National Institute of Allergy and Infectious Diseases (NIAID)

Autologous stem cells will be injected after conditioning

Allogeneic stem cells will be injected after conditioning

Autologous stem cells will be injected after conditioning
Autologous hematopoietic stem cell transplantation: Autologous hematopoietic stem cells will be injected after conditioning

Autologous Hematopoietic Stem Cell Transplantation

Allogeneic stem cells will be injected after conditioning
Allogeneic stem cell transplantation: Allogeneic stem cells will be injected after conditioning

Allogeneic Stem Cell Transplantation

Total

Region of Enrollment

Daily assessment will be made with regards to toxicity by one of the protocol investigators.National Cancer Institute Common Toxicity Criteria will be used to grade all non-hematologic toxicities. Toxicity grades as follows: 1 = Mild; 2 = Moderate; 3 = Severe and undesirable; 4 = life threatening or disabling ; 5 = Death

Presence of Toxicity

Survival

Worsening symptoms, pulmonary function studies, cardiac function and arrhythmia including EKG assessments, and neurological symptoms.

Time to Disease Progression

Dr Richard Burt, Chief, Division of Immunotherapy, Department of Medicine

Sarcoidosis

Autologous hematopoietic stem cells will be injected after conditioning

Autologous hematopoietic stem cell transplantation

Allogeneic stem cell transplantation

Northwestern University, Feinberg School of Medicine

Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis

Hematopoietic Stem Cell Transplant in Patients With Refractory Sarcoidosis: A Phase I/II Trial

Richard Burt, MD

Northwestern University

Autologous Stem Cell Transplant will be performed on eligible patients

Allogeneic Stem Cell Transplant will be performed on eligible patients

Autologous Stem Cell Transplant will be performed on eligible patients
Autologous Stem Cell Transplant: Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning

Autologous Stem Cell Transplant

Allogeneic Stem Cell Transplant will be performed on eligible patients
Allogeneic Stem Cell Transplant: Allogeneic Stem Cell Transplant will be performed after conditioning

Allogeneic Stem Cell Transplant

Dr Richard Burt

Vasculitis

Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning

Allogeneic Stem Cell Transplant will be performed after conditioning

Cyclophosphamide

A rabbit polyclonal antibody to lymphocyte

ATG (rabbit)

G-CSF

Humanized monoclonal antibody against CD52 antigen

Campath-1h

Fludarabine

Tacrolimus

Mesna is a drug used to protect the bladder from the effects of the chemotherapy drugs

Mesna

Hematopoietic Stem Cell Support in Vasculitis

High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome

viremia/misselijkheid

Ivermectin and Nitazoxanide Combination Therapy for COVID-19

Emtricitabine/Tenofovir Alafenamide as Salvage ART

Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis

Hematopoietic Stem Cell Support in Vasculitis

De meest complete database met geneeskrachtige kruiden, ondersteund door de wetenschap